Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s traded shares stood at 0.88 million during the last session, with the company’s beta value hitting 0.54. At the close of trading, the stock’s price was $9.00, to imply an increase of 5.88% or $0.5 in intraday trading. The PHAT share’s 52-week high remains $19.71, putting it -119.0% down since that peak but still an impressive 32.56% since price per share fell to its 52-week low of $6.07. The company has a valuation of $615.40M, with an average of 0.9 million shares in intraday trading volume over the past 10 days and average of 1.32 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Phathom Pharmaceuticals Inc (PHAT), translating to a mean rating of 1.25. Of 10 analyst(s) looking at the stock, 2 analyst(s) give PHAT a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.07.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information
After registering a 5.88% upside in the last session, Phathom Pharmaceuticals Inc (PHAT) has traded red over the past five days. The 5-day price performance for the stock is 1.47%, and -50.00% over 30 days. With these gigs, the year-to-date price performance is -1.42%. Short interest in Phathom Pharmaceuticals Inc (NASDAQ:PHAT) saw shorts transact 14.66 million shares and set a 8.61 days time to cover.
The extremes give us $12 and $28 for target low and target high price respectively. As such, PHAT has been trading -211.11% off suggested target high and -33.33% from its likely low.
Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts
Looking at statistics comparing Phathom Pharmaceuticals Inc share performance against respective industry, we note that the company has underperformed competitors. Phathom Pharmaceuticals Inc (PHAT) shares are -15.09% down over the last 6 months, with its year-to-date growth rate lower than industry average at -71.54% against 17.50%. The rating firms project that company’s revenue will grow 7,471.03% compared to the previous financial year.
Revenue forecast for the current quarter as set by 7 analysts is 26.04M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 28.02M.Earnings reports from the last fiscal year show that sales brought in 682k and 1.91M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 3,718.56% before jumping 1,365.71% in the following quarter.
PHAT Dividends
Phathom Pharmaceuticals Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s Major holders
Phathom Pharmaceuticals Inc insiders hold 7.70% of total outstanding shares, with institutional holders owning 110.57% of the shares at 119.78% float percentage. In total, 110.57% institutions holds shares in the company, led by FRAZIER LIFE SCIENCES MANAGEMENT, L.P. As of 2024-06-30, the company held over 10.11 million shares (or 17.3189% of shares), all amounting to roughly $104.13 million.
The next major institution holding the largest number of shares is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with 7.46 million shares, or about 12.788% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $76.89 million.
We also have PGIM Jennison Health Sciences Fd and Fidelity Rutland Square Tr II-Strategic Advisers U.S. Total Stock Fd as the top two Mutual Funds with the largest holdings of the Phathom Pharmaceuticals Inc (PHAT) shares. Going by data provided on Sep 30, 2024, PGIM Jennison Health Sciences Fd holds roughly 1.97 shares. This is just over 2.89% of the total shares, with a market valuation of $17.75 million. Data from the same date shows that the other fund manager holds a little less at 1.75, or 2.56% of the shares, all valued at about 15.74 million.
